United BioSource Corporation, Goring-on-Thames, UK.
Acta Neurol Scand. 2010 Oct;122(4):270-7. doi: 10.1111/j.1600-0404.2009.01309.x. Epub 2009 Dec 28.
Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment.
Patients completed cognition assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated.
The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months.
There are a number of methodological problems with current cognition assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.
阿尔茨海默病评估量表认知子量表（ADAS-Cog）已成为认知的标准临床试验结局，但已被认为在包括认知领域的覆盖范围、敏感性和标准化在内的领域存在不足。计算机化测试组合可能会解决其中一些问题。认知药物研究计算机化评估 (CDR) 系统在阿尔茨海默病（AD）中得到验证。本研究旨在进一步评估其在 ADAS-Cog、简易精神状态检查 (MMSE) 和脑脊液 (CSF) 生物标志物以及心理测量特性方面的有效性，在一群接受稳定乙酰胆碱酯酶抑制剂治疗的阿尔茨海默病患者中。
患者在基线和 6 个月后完成认知评估、CSF 和血液采样。对 65 名患者的数据进行了评估。
CDR 系统在该人群中表现出良好的心理测量特性。精神运动速度测量值可能显示出在 6 个月内下降的敏感性。
目前临床试验的认知评估方法存在许多方法学问题。计算机化测量值，特别是毫秒反应时间测量值，可能会解决其中的许多问题。
